2025 Community Routes: Access To Mental Health Care Grants Awarded To Clinics In Alabama, Mississippi, And Texas, Funded By Teva Pharmaceuticals

The broad market exchange-traded fund SPDR S&P 500 ETF Trust was up 0.1% and the actively traded Invesco QQQ Trust advanced 0.3% in Friday's premarket activity as investors remain cautious amid ongoing tariff uncertainties and a subdued retail outlook.

US stock futures were mixed, with S&P 500 Index futures up 0.1%, Dow Jones Industrial Average futures advancing 0.3%, and Nasdaq futures gaining 0.3% before the start of regular trading.

The purchasing managers' index report from S&P Global (SPGI) for February will be released at 9:45 am ET.

Reports releasing at 10 am ET include January's existing home sales report, the final University of Michigan consumer sentiment report for February, and the Q4 services survey.

The weekly Baker Hughes domestic oil-and-gas rig count is due at 1 pm ET.

Federal Reserve Vice Chair Philip Jefferson and San Francisco Fed President Mary Daly are both slated to speak at 11:30 am ET.

In premarket activity, bitcoin was up by 0.1% and the cryptocurrency fund ProShares Bitcoin Strategy ETF was 0.1% higher.

Power Play:

Consumer

The Consumer Staples Select Sector SPDR Fund was flat, while the Vanguard Consumer Staples Fund was up 0.7%. The iShares US Consumer Staples ETF retreated 0.01%, and the Consumer Discretionary Select Sector SPDR Fund gained 0.2%. The VanEck Retail ETF and the SPDR S&P Retail ETF were inactive.

Celsius Holdings shares were up 32% pre-bell after the company said Thursday it agreed to acquire energy drink maker Alani Nutrition in a cash-and-stock deal worth about $1.80 billion.

Winners and Losers:

Technology

Technology Select Sector SPDR Fund was flat, and the iShares US Technology ETF was 0.4% higher, while the iShares Expanded Tech Sector ETF was inactive. Among semiconductor ETFs, SPDR S&P Semiconductor ETF was flat, while the iShares Semiconductor ETF gained by 0.1%.

Innodata shares were up more than 11% in recent premarket activity Friday after the company overnight reported higher Q4 earnings and sales.

Industrial

Industrial Select Sector SPDR Fund , the Vanguard Industrials Index Fund , and the iShares US Industrials ETF (IYJ) were inactive.

Atmus Filtration Technologies stock was up 7.2% before the opening bell after the company reported higher Q4 adjusted earnings and revenue that also beat FactSet analysts' estimates.

Energy

The iShares US Energy ETF was inactive, while the Energy Select Sector SPDR Fund was down by 0.4%.

Solaris Energy Infrastructure stock was up 3.2% before Friday's opening bell after the company reported Q4 adjusted earnings late Thursday in line with FactSet analyst estimates, with the higher revenue beating expectations.

Health Care

The Health Care Select Sector SPDR Fund advanced 0.02%. The Vanguard Health Care Index Fund was down 0.04% while the iShares US Healthcare ETF was flat. The iShares Biotechnology ETF gained 0.2%.

Teva Pharmaceutical Industries stock was 2.7% higher and Alvotech was up 3% premarket Friday after the companies said that the Selarsdi injection is now available in the US to treat psoriatic arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, pediatric plaque psoriasis and pediatric psoriatic arthritis.

Financial

Financial Select Sector SPDR Fund advanced 0.2%. Direxion Daily Financial Bull 3X Shares was up 0.6%, while its bearish counterpart Direxion Daily Financial Bear 3X Shares was 0.5% lower.

Huize H shares were down 2.3% pre-bell Friday nearly reversing the 2.5% gains in the previous close. The company said it has integrated DeepSeek AI into its insurance app.

Commodities

Front-month US West Texas Intermediate crude oil retreated 0.8% to $71.87 per barrel on the New York Mercantile Exchange. Natural gas rose 3% to $4.28 per 1 million British Thermal Units. United States Oil Fund was down 0.8% while the United States Natural Gas Fund was 1.6% higher.

Gold futures for April declined 0.4% to $2,945.60 an ounce on the Comex, while silver futures retreated 0.4% to $33.67 an ounce. SPDR Gold Shares were down 0.3%, and the iShares Silver Trust was 0.2% higher.

Teva Pharmaceutical Industries US affiliate and Alvotech said Friday that the Selarsdi injection is now available in the US to treat psoriatic arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, pediatric plaque psoriasis and pediatric psoriatic arthritis.

Selarsdi is biosimilar to Stelara and it is the second biosimilar now available in the country under the Teva and Alvotech collaboration, they added.

The US Food and Drug Administration provisionally determined that Selarsdi is interchangeable with the reference biologic Stelara after the first interchangeable biosimilar expires, on April 30, the parties said.

Teva Pharmaceutical's stock rose 2.7%, while Alvotech's shares were up 3% in recent Friday premarket activity.

Amicus Therapeutics FOLD reported fourth-quarter 2024 adjusted earnings of 9 cents per share, which missed the Zacks Consensus Estimate of 10 cents. The company had reported earnings of 1 cent per share in the year-ago quarter.

See the Zacks Earnings Calendar to stay ahead of market-making news.

Revenues in the fourth quarter totaled $149.7 million, up 30% year over year on a reported basis and a constant-currency (cc) basis. The figure marginally beat the Zacks Consensus Estimate of $149 million. The top line comprised sales of Galafold (migalastat), which is approved for Fabry disease and the newly approved combo drug, Pombiliti + Opfolda.

The FDA approved Pombiliti + Opfolda, a two-component therapy for treating late-onset Pompe disease, in September 2023.

The top-line increased year over year owing to higher revenues from Galafold sales and incremental revenues from the sale of Pombiliti + Opfolda. Both Fabry disease and Pompe disease are rare diseases. Amicus is currently advancing ongoing studies to broaden labels in Fabry and Pompe diseases.

In the past year, shares of Amicus have plunged 29.5% compared with the industry’s decline of 8.1%.

Richard D Francis, President and CEO, on February 15, 2025, sold 75,506 shares in Teva Pharmaceutical Industries for $1,279,661. Following the Form 4 filing with the SEC, Francis has control over a total of 209,444 common shares of the company, with 209,444 shares held directly.

SEC Filing:

www.sec.gov/Archives/edgar/data/818686/000095017025023126/xslF345X05/ownership.xml